Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E.coli developed by Janssen, currently in Phase 3.